Non-compete restriction in pharmaceutical FDI: clauses prohibited except in special cases with FIPB approval now required Foreign direct investment in pharmaceuticals remains at 100% for both greenfield (automatic approval) and brownfield (government approval subject to conditions). Newly imposed restriction disallows non-compete clauses except in exceptional cases with prior approval from the designated foreign investment approval authority; this restriction takes immediate effect.
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Non-compete restriction in pharmaceutical FDI: clauses prohibited except in special cases with FIPB approval now required
Foreign direct investment in pharmaceuticals remains at 100% for both greenfield (automatic approval) and brownfield (government approval subject to conditions). Newly imposed restriction disallows non-compete clauses except in exceptional cases with prior approval from the designated foreign investment approval authority; this restriction takes immediate effect.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 
Join Channel
TaxTMI 
